CERES NANOSCIENCES, INC. – Trademark Portfolio

Entity Type: 03

CERES NANOSCIENCES, INC. holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 3 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include NANOTRAP and CERES NANO. The owner is based in MANASSAS, VA.

9460 Innovation Dr

MANASSAS, VA 20110

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

CERES NANOSCIENCES, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (3 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does CERES NANOSCIENCES, INC. have?

CERES NANOSCIENCES, INC. has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned.

What trademark classes does CERES NANOSCIENCES, INC. file in?

CERES NANOSCIENCES, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 10 (Medical Apparatus). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are CERES NANOSCIENCES, INC.'s most well-known trademarks?

CERES NANOSCIENCES, INC.'s registered trademark portfolio includes well-known marks such as NANOTRAP and CERES NANO. These are among 2 currently registered trademarks in the portfolio.

What is CERES NANOSCIENCES, INC.'s trademark registration success rate?

CERES NANOSCIENCES, INC. has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.